Literature DB >> 17400591

Estimated life expectancy of Parkinson's patients compared with the UK population.

Lianna S Ishihara1, Anne Cheesbrough, Carol Brayne, Anette Schrag.   

Abstract

OBJECTIVE: To calculate the best possible estimates for age specific life expectancy (LE) and anticipated age at the time of death (AAD) in patients with Parkinson's disease (PD) compared with the general population in the UK. These may be of greater value to patients than standardised mortality ratios (SMRs), which are usually reported in studies on mortality in PD.
METHODS: A literature review identified articles with data on age stratified life expectancy or SMRs to calculate estimations of LE using the Gompertz function and data on mortality and LE in the UK from the Office of National Statistics and Actuarial Department for the year 2003.
RESULTS: Two UK studies and four from Western Europe were used to estimate LE and AAD for patients with PD from SMRs. The mean LEs of patients with PD compared with the general population were: 38 (SD 5) years for onset between 25 and 39 years compared with 49 (SD 5) years; 21 (SD 5) years for onset between 40 and 64 years compared with 31 (SD 7) years; and 5 (SD 4) years for onset age > or = 65 years compared with 9 (SD 5) years. The average AAD of patients with PD with onset between 25 and 39 years was 71 (SD 3) years and considerably lower than that of the general population (82 (SD 2) years). The difference between average AAD for older individuals with PD (onset > or = 65 years) and the general population was smaller, with an AAD of approximately 88 (SD 7) years compared with 91 (SD 5) years.
CONCLUSIONS: The calculations showed that LE and AAD in PD are reduced for all onset ages but this reduction is greatest in individuals with a young onset. While the results are average estimates, these can provide useful indications of LE and AAD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400591      PMCID: PMC2095626          DOI: 10.1136/jnnp.2006.100107

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  51 in total

1.  Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.

Authors:  P T Donnan; D T Steinke; C Stubbings; P G Davey; T M MacDonald
Journal:  Neurology       Date:  2000-12-26       Impact factor: 9.910

2.  Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease.

Authors:  J L Montastruc; K Desboeuf; M Lapeyre-Mestre; J M Senard; O Rascol; C Brefel-Courbon
Journal:  Mov Disord       Date:  2001-05       Impact factor: 10.338

3.  Fun with Gompertz.

Authors:  J H Pollard
Journal:  Genus       Date:  1991 Jan-Jun

4.  Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study.

Authors:  M Guttman; P M Slaughter; M E Theriault; D P DeBoer; C D Naylor
Journal:  Neurology       Date:  2001-12-26       Impact factor: 9.910

5.  Prognosis with Parkinson's disease in europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.

Authors:  K Berger; M M Breteler; C Helmer; D Inzitari; L Fratiglioni; C Trenkwalder; A Hofman; L J Launer
Journal:  Neurology       Date:  2000       Impact factor: 9.910

6.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.

Authors:  A Ascherio; S M Zhang; M A Hernán; I Kawachi; G A Colditz; F E Speizer; W C Willett
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

7.  Survival of Parkinson's disease patients in a large prospective cohort of male health professionals.

Authors:  Honglei Chen; Shumin M Zhang; Michael A Schwarzschild; Miguel A Hernán; Alberto Ascherio
Journal:  Mov Disord       Date:  2006-07       Impact factor: 10.338

8.  Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.

Authors:  A J Lees; R Katzenschlager; J Head; Y Ben-Shlomo
Journal:  Neurology       Date:  2001-11-13       Impact factor: 9.910

9.  Parkinson disease survival: a population-based study.

Authors:  L Morgante; G Salemi; F Meneghini; A E Di Rosa; A Epifanio; F Grigoletto; P Ragonese; F Patti; A Reggio; R Di Perri; G Savettieri
Journal:  Arch Neurol       Date:  2000-04

10.  Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.

Authors:  A J Lees
Journal:  BMJ       Date:  1995-12-16
View more
  25 in total

1.  Estimation of Parkinson's disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach.

Authors:  O Chillag-Talmor; N Giladi; S Linn; T Gurevich; B El-Ad; B Silverman; N Friedman; C Peretz
Journal:  J Neurol       Date:  2012-07-07       Impact factor: 4.849

2.  Is Parkinson's Disease Associated with Increased Mortality, Poorer Outcomes Scores, and Revision Risk After THA? Findings from the Swedish Hip Arthroplasty Register.

Authors:  Alex Leigh Wojtowicz; Maziar Mohaddes; Daniel Odin; Erik Bülow; Szilard Nemes; Peter Cnudde
Journal:  Clin Orthop Relat Res       Date:  2019-06       Impact factor: 4.176

Review 3.  Basic science in Parkinson's disease: its impact on clinical practice.

Authors:  Jörg B Schulz; Manfred Gerlach; Gabriele Gille; Wilfried Kuhn; Martina Müngersdorf; Peter Riederer; Martin Südmeyer; Albert Ludolph
Journal:  J Neurol       Date:  2011-05       Impact factor: 4.849

4.  Predictors of survival in patients with Parkinson disease.

Authors:  Allison W Willis; Mario Schootman; Nathan Kung; Bradley A Evanoff; Joel S Perlmutter; Brad A Racette
Journal:  Arch Neurol       Date:  2012-05

5.  Amelioration of the nigrostriatal pathway facilitated by ultrasound-mediated neurotrophic delivery in early Parkinson's disease.

Authors:  Maria Eleni Karakatsani; Shutao Wang; Gesthimani Samiotaki; Tara Kugelman; Oluyemi O Olumolade; Camilo Acosta; Tao Sun; Yang Han; Hermes A S Kamimura; Vernice Jackson-Lewis; Serge Przedborski; Elisa Konofagou
Journal:  J Control Release       Date:  2019-04-04       Impact factor: 9.776

6.  Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease.

Authors:  Marian L Evatt; Mahlon R Delong; Natasha Khazai; Ami Rosen; Shirley Triche; Vin Tangpricha
Journal:  Arch Neurol       Date:  2008-10

Review 7.  Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention--A Comparison with Parkinson's Disease.

Authors:  S DeVaughn; E M Müller-Oehring; B Markey; H M Brontë-Stewart; T Schulte
Journal:  Neuropsychol Rev       Date:  2015-11-17       Impact factor: 7.444

8.  Palliative care in Parkinson's disease.

Authors:  Janis M Miyasaki
Journal:  Curr Neurol Neurosci Rep       Date:  2013-08       Impact factor: 5.081

9.  Effectiveness of a Long-Term, Home-Based Aerobic Exercise Intervention on Slowing the Progression of Parkinson Disease: Design of the Cyclical Lower Extremity Exercise for Parkinson Disease II (CYCLE-II) Study.

Authors:  Jay L Alberts; Anson B Rosenfeldt; Cielita Lopez-Lennon; Erin Suttman; A Elizabeth Jansen; Peter B Imrey; Leland E Dibble
Journal:  Phys Ther       Date:  2021-11-01

Review 10.  Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?

Authors:  Jean-François Daneault; Benoit Carignan; Abbas F Sadikot; Michel Panisset; Christian Duval
Journal:  BMC Med       Date:  2013-03-20       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.